August 4, 2021: There was a CPhI Live Panel discussion entitled: “The Real Cost of Bringing Manufacturing Home”. The panel discussion is available on demand (see below).

Many years before the pandemic the industry has highlighted the importance of a globalized supply chain and in particular the heavy reliance on Asian suppliers. The situation fueled calls from political leaders and lawmakers for U.S. manufacturers to start producing critical supplies domestically. But what will be the cost of bringing manufacturing home, and who will the burden lie on?

If you are registered for CPhI North America, you can log on and view the webcast replay of the live panel discussion that featured Wayne Weiner (Pharmatech Solutions), David Gaugh (Sr. VP for Sciences and Regulatory at Association for Accessible Medicines), Bikash Chatterjee (CEO at Pharmatech), and Ken Drew (VP Flamma USA).

Chignolo D’Isola, Bergamo, Italy – June 22, 2021 – Flamma was recently spotlighted in Chimica Oggi-Chemistry Today. The article is entitled “A Word With Flamma” and featured a question and answer segment with Kenneth Drew, Ph.D., VP Flamma USA. Drew speaks about Flamma’s long history, building relationships with customers, reliable supply chains, and much more.

You can read the article by going to this page or you can download it here.

About Flamma:

FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

The Malvern, PA site located outside Philadelphia provides Flamma with the ability to service customers looking to keep materials within the USA for pre-clinical/early stage clinical development as well as small scale commercial manufacturing.

Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m³ and over 600 employees, see why Flamma should be your next contract manufacturer. FLAMMA – THE THINKING CDMO^TM.

Chemical and Engineering News (C&EN) did a feature on Flamma that told the story of Flamma and Flamma’s Dalian, China facility- Flamma Honkai.

You can read this article here.